Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Top Cited Papers
- 15 September 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 112 (6) , 2199-2204
- https://doi.org/10.1182/blood-2008-03-143602
Abstract
Previous small studies have reported familial clustering of myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). We identified 6217 PV, 2838 ET, 1172 MF, and 812 MPN unclassifiable (NOS) patients diagnosed in Sweden, 43 550 controls, and first-degree relatives of cases (n = 24 577) and controls (n = 99 542). Using a marginal survival model, we calculated relative risks (RRs) and 95% confidence intervals as measures of familial aggregation. Relatives of MPN patients had significantly increased risks of PV (RR = 5.7; 3.5-9.1), ET (RR = 7.4; 3.7-14.8), and MPN NOS (RR = 7.5; 2.7-20.8). Analyses stratified by type of first-degree relative revealed consistently higher risks for siblings, compatible with a model of recessive genetic inheritance, which can be confirmed only by identifying the susceptibility gene(s). Mean age at MPN diagnosis was not different (P = .20) for affected relatives of cases (57.5 years) versus controls (60.6 years), and risk of MPN by age was not different for parents versus offspring of MPN cases (P = .10), providing no support for anticipation. Relatives of MPN patients had a borderline increased risk of chronic myeloid leukemia (CML; RR = 1.9; 0.9-3.8; P = .09). Our findings of 5- to 7-fold elevated risk of MPNs among first-degree relatives of MPN patients support the hypothesis that common, strong, shared susceptibility genes predispose to PV, ET, MF, and possibly CML.This publication has 22 references indexed in Scilit:
- Host genetic variation contributes to phenotypic diversity in myeloproliferative disordersBlood, 2008
- 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosisEuropean Journal of Haematology, 2008
- Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease AnticipationJournal of Clinical Oncology, 2007
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003International Journal of Cancer, 2007
- Thrombosis in Myeloproliferative Disorders: Prevalence, Prognostic Factors, and the Role of Leukocytes and JAK2V617FSeminars in Thrombosis and Hemostasis, 2007
- Oncogenes in Myeloproliferative DisordersCell Cycle, 2007
- Biology and Treatment of Primary MyelofibrosisHematology-American Society Hematology Education Program, 2007
- Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disordersBlood, 2006
- Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disordersBlood, 2006